The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program
Open accessAbstract
Purpose: To offer minimized risk-adapted adjuvant treatment on a nationwide basis for patients with clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT). The aim was to reduce the risk of relapse and thereby reducing the need of later salvage chemotherapy while maintaining a high cure rate. Patients and Methods: From 1998 to 2005, 745 Norwegian and Swedish patients were included into a prospective, community-based multicenter Swedish and Norwegian Testicular Cancer Project (SWENOTECA) management program. Treatment strategy depended on the presence or absence of vascular tumor invasion (VASC). VASC-positive patients were recommended brief adjuvant chemotherapy (ACT) with bleomycin, etoposide, and cisplatin (BEP), whereas VASC-negative patients could choose between ACT and surveillance. Results: At a median follow-up of 4.7 years, there have been 51 relapses. On surveillance, 41.7% of VASC+ patients relapsed, compared with 13.2% of VASC− patients. After one course of BEP, 3.2% of VASC+ and 1.3% of VASC− patients relapsed. The toxicity of adjuvant BEP was low. Eight patients have died, none died from progressive disease. Conclusion: One course of adjuvant BEP reduces the risk of relapse by approximately 90% in both VASC+ and VASC− CS1 NSGCT, and may be a new option as initial treatment for all CS1 NSGCT. One course of adjuvant BEP for VASC+ CS1 reduces the total burden of chemotherapy compared with surveillance or two courses of BEP. SWENOTECA currently recommends one course of BEP as standard treatment of VASC+ CS1 NSGCT, whereas both surveillance and one course of BEP are options for VASC− CS1 NSGCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Cavallin-Ståhl, E., et al. (2008) · European Urology · doi:10.1016/j.eururo.2007.12.024 · Cited by 617
Self-citationCardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer
Huddart, R. A., Norman, A., Shahidi, M., Horwich, A., Coward, D., Nicholls, J., & Dearnaley, D. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.173 · Cited by 547
Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer
Meinardi, M. T., Gietema, J. A., van der Graaf, W. T. A., van Veldhuisen, D. J., Runne, M. A., Sluiter, W. J., de Vries, E. G. E., Willemse, P. B. H., Mulder, N. H., van den Berg, M. P., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1725 · Cited by 489
Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer
Travis, L. B., Curtis, R. E., Fraumeni, J. F., Boice, J. D., Storm, H., Andersson, M., Hall, P., Bergfeldt, K., Holowaty, E., Clarke, E. A., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.19.1429 · Cited by 488
van den Belt-Dusebout, A. W., de Wit, R., Gietema, J. A., Horenblas, S., Louwman, M. W. J., Ribot, J. G., Hoekstra, H. J., Ouwens, G. M., Aleman, B. M. P., & van Leeuwen, F. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5296 · Cited by 453
Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer
van den Belt-Dusebout, A. W., Nuver, J., de Wit, R., Gietema, J. A., ten Bokkel Huinink, W. W., Rodrigus, P. T. R., Schimmel, E. C., Aleman, B. M. P., & van Leeuwen, F. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7193 · Cited by 345
Albers, P., Siener, R., Krege, S., Schmelz, H.-U., Dieckmann, K.-P., Heidenreich, A., Kwasny, P., Pechoel, M., Lehmann, J., Kliesch, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0899 · Cited by 337
Paternity Following Treatment for Testicular Cancer
Brydøy, M., Fosså, S. D., Klepp, O., Bremnes, R. M., Wist, E. A., Wentzel-Larsen, T., & Dahl, O. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji339 · Cited by 272
Self-citationTreatment-Associated Leukemia Following Testicular Cancer
Travis, L. B. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.14.1165 · Cited by 254
COMBINED MANAGEMENT OF MALIGNANT TERATOMA OF THE TESTIS
Peckham, M. J., Barrett, A., Mcelwain, T. J., & Hendry, W. F. (1979) · The Lancet · doi:10.1016/s0140-6736(79)90288-5 · Cited by 246
Le Deley, M.-C., Leblanc, T., Shamsaldin, A., Raquin, M.-A., Lacour, B., Sommelet, D., Chompret, A., Cayuela, J.-M., Bayle, C., Bernheim, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.100 · Cited by 216
Nuver, J., Smit, A. J., Wolffenbuttel, B. H. R., Sluiter, W. J., Hoekstra, H. J., Sleijfer, D. T., & Gietema, J. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.176 · Cited by 190
Components of the metabolic syndrome in long-term survivors of testicular cancer
Haugnes, H. S., Aass, N., Fosså, S. D., Dahl, O., Klepp, O., Wist, E. A., Svartberg, J., Wilsgaard, T., & Bremnes, R. M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl372 · Cited by 183
Self-citationStudy of anxiety disorder and depression in long-term survivors of testicular cancer
Dahl, A. A., Haaland, C. F., Mykletun, A., Bremnes, R., Dahl, O., Klepp, O., Wist, E., & Fosså, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.061 · Cited by 176
Self-citationPredictors of Occult Metastasis in Clinical Stage I Nonseminoma: A Systematic Review
Vergouwe, Y., Steyerberg, E. W., Eijkemans, M. J. C., Albers, P., & Habbema, J. D. F. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.094 · Cited by 165
Nuver, J., Smit, A. J., Wolffenbuttel, B. H., Sluiter, W. J., Hoekstra, H. J., Sleijfer, D. T., & Gietema, J. A. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)01043-8 · Cited by 163
Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis
Oldenburg, J., Martin, J. M., & Fosså, S. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1836 · Cited by 151
Gels, M. E., Hoekstra, H. J., Sleijfer, D. T., Marrink, J., de Bruijn, H. W., Molenaar, W. M., Freling, N. J. M., Droste, J. H. J., & Koops, H. S. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1188 · Cited by 150
Mykletun, A., Dahl, A. A., Haaland, C. F., Bremnes, R. M., Dahl, O., Klepp, O., Wist, E., & Fosså, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.048 · Cited by 126
Self-citationSperm DNA integrity in testicular cancer patients
Ståhl, O., Eberhard, J., Jepson, K., Spano, M., Cwikiel, M., Cavallin-Ståhl, E. K., & Giwercman, A. (2006) · Human Reproduction · doi:10.1093/humrep/del292 · Cited by 117
Oliver, R. T. D., Ong, J., Shamash, J., Ravi, R., Nagund, V., Harper, P., Ostrowski, M. J., Sizer, B., LeVay, J. H., Robinson, A. C. R., et al. (2004) · Urology · doi:10.1016/j.urology.2003.10.023 · Cited by 100
Controversies in the Management of Clinical Stage I Testis Cancer
de Wit, R., & Fizazi, K. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9434 · Cited by 94
Cited by
Guidelines on Testicular Cancer: 2015 Update
Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., Horwich, A., Laguna, M. P., Nicolai, N., & Oldenburg, J. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.044 · Cited by 670
Self-citationCheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0029-0 · Cited by 462
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450
Rajpert-De Meyts, E., McGlynn, K. A., Okamoto, K., Jewett, M. A. S., & Bokemeyer, C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00991-5 · Cited by 398
Testicular Cancer — Discoveries and Updates
Hanna, N. H., & Einhorn, L. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1407550 · Cited by 345
Metadata
- Authors
- Tandstad, T., Dahl, O., Cohn-Cedermark, G., Cavallin-Stahl, E., Stierner, U., Solberg, A., Langberg, C., Bremnes, R. M., Laurell, A., Wijkstrøm, H., & Klepp, O.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-05-01
- Volume
- 27
- Issue
- 13
- Pages
- 2122-2128
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2065241538
- Cited by
- 262
- References
- 25
- FWCI
- 19.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.